Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 53, 2018 - Issue 8
Submit an article Journal homepage
781
Views
37
CrossRef citations to date
0
Altmetric
Original Article

Success and safety of high infliximab trough levels in inflammatory bowel disease

David DrobneDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; ;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2734-675X
ORCID Icon,
Tina KurentDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Sasa GolobDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Polona SveglDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Polona RajarDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Sara TerzicDepartment of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Matic KozeljDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Gregor NovakDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Natasa SmrekarDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Samo PlutDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; ;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia;
,
Nejc SeverDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Luka StrnisaDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; ;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia;
,
Jurij HanzelDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Jernej BreceljMedical Faculty, University of Ljubljana, Ljubljana, Slovenia; ;Department of Gastroenterology Hepatology and Nutrition, Children's Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Darja UrlepDepartment of Gastroenterology Hepatology and Nutrition, Children's Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Josko OsredkarClinical Institute of Clinical Chemistry, Biochemistry University Medical Centre Ljubljana, Ljubljana, Slovenia
,
Matjaz HomanMedical Faculty, University of Ljubljana, Ljubljana, Slovenia; ;Department of Gastroenterology Hepatology and Nutrition, Children's Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Rok OrelMedical Faculty, University of Ljubljana, Ljubljana, Slovenia; ;Department of Gastroenterology Hepatology and Nutrition, Children's Hospital University Medical Centre Ljubljana, Ljubljana, Slovenia;
,
Borut StabucDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; ;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia;
,
Ivan FerkoljDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; ;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia;
&
Alojz SmidDepartment of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia; ;Medical Faculty, University of Ljubljana, Ljubljana, Slovenia;
show all
Pages 940-946 | Received 30 Apr 2018, Accepted 05 Jun 2018, Published online: 10 Jul 2018

Citations (37)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anne S Strik, Sophie E Berends & Mark Löwenberg. (2019) Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. Expert Review of Clinical Pharmacology 12:9, pages 885-891.
Read now
Neeraj Narula, Brian Lauzon & John K. Marshall. (2019) Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 54:6, pages 712-717.
Read now

Articles from other publishers (35)

Anke L. Nguyen, Peter R. Gibson, Richard N. Upton, Diane R. Mould & Miles P. Sparrow. (2023) Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis. The Journal of Clinical Pharmacology.
Crossref
Clarissa A. Rentsch, Mark G. Ward, Raphael P. Luber, Kirstin M. Taylor, David J. Gibson, Belinda Headon, Ourania Rosella, Heidi Y. Su, Antony B. Friedman, Michael Dooley, Miles P. Sparrow & Peter R. Gibson. (2023) Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease. Therapeutic Drug Monitoring 45:3, pages 383-391.
Crossref
Kathryn Gazelakis, Isabel Chu, Catherine Martin & Miles P. Sparrow. (2023) Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal Medicine Journal.
Crossref
Christine Martinez-Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill & Janet Addison. (2022) PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients. Journal of Pediatric Gastroenterology & Nutrition 76:4, pages 451-459.
Crossref
Merle Claßen & André Hoerning. (2023) Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies. Children 10:4, pages 634.
Crossref
Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, Vito Guerra, Antonio Lippolis, Mauro Mastronardi & Palma Aurelia Iacovazzi. (2023) 90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients. International Journal of Molecular Sciences 24:4, pages 3955.
Crossref
Lorenzo Cantarelli, Marta Carrillo Palau, Manuel Hernandez Guerra, Gloria Julia Nazco Casariego & Fernando Gutierrez Nicolás. (2023) Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. Medicina Clínica 160:3, pages 107-112.
Crossref
Lorenzo Cantarelli, Marta Carrillo Palau, Manuel Hernandez Guerra, Gloria Julia Nazco Casariego & Fernando Gutierrez Nicolás. (2023) Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. Medicina Clínica (English Edition) 160:3, pages 107-112.
Crossref
Esteban Fuentes-Valenzuela, Francisco Javier García-Alonso, Carlos Maroto-Martín, Laura Juan Casamayor, José Antonio Garrote, Rosendo Almendros Muñoz, Ángel De Prado, Alejando Vara Castrodeza, María Ángeles Marinero, Raquel Calleja Carbajosa & Jesús Barrio. (2023) Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study . Inflammatory Bowel Diseases.
Crossref
Abhik Bhattacharya, Daniel Travis, Mark T. Osterman, James D. Lewis, Bhavana Bhagya Rao, Helen Lee & Gary R. Lichtenstein. (2023) Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn’s Disease. Journal of Clinical Gastroenterology 57:1, pages 66-73.
Crossref
Zvonimir Petric, Joao Goncalves & Paulo Paixao. (2022) Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars. Pharmaceutics 14:9, pages 1766.
Crossref
Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin & Shaji Sebastian. (2022) Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Frontiers in Medicine 9.
Crossref
Silvia Marquez-Megias, Ricardo Nalda-Molina, Javier Sanz-Valero, Patricio Más-Serrano, Marcos Diaz-Gonzalez, Maria Remedios Candela-Boix & Amelia Ramon-Lopez. (2022) Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. Pharmaceutics 14:5, pages 1009.
Crossref
Laura Sirmai, Anne-Laure Pelletier, Nathalie Gault, Camille Zallot, Guillaume Bouguen, Dominique Bouchard, Pascale Roland Nicaise, Marine Peyneau, Sandrine Sironneau, Marcelo De Carvalho Bittencourt, Antoine Petitcollin, Pedro Fernandez, Xavier Roblin, Laurent Siproudhis & Laurent Abramowitz. (2022) Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World Journal of Gastroenterology 28:9, pages 961-972.
Crossref
Zohar Ben-Shatach, Tomer Ziv-Baran, Ella Fudim, Miri Yavzori, Orit Picard, Asaf Levartovsky, Limor Selinger, Batia Weiss, Uri Kopylov, Rami Eliakim & Bella Ungar. (2022) Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therapeutic Advances in Gastroenterology 15, pages 175628482210833.
Crossref
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli & Ioannis E. Koutroubakis. (2021) Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. Intestinal Research 19:4, pages 461-467.
Crossref
Tim Raine, Bram Verstockt, Uri Kopylov, Konstantinos Karmiris, Rimma Goldberg, Raja Atreya, Johan Burisch, John Burke, Pierre Ellul, Charlotte Hedin, Stefan D Holubar, Konstantinos Katsanos, Triana Lobaton, Carsten Schmidt & Garret Cullen. (2021) ECCO Topical Review: Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis 15:10, pages 1605-1620.
Crossref
Maya Zvuloni, Manar Matar, Rachel Levi, Dror S. Shouval, Raanan Shamir & Amit Assa. (2021) High anti-TNFα Concentrations are Not Associated With More Adverse Events in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition Publish Ahead of Print.
Crossref
Joško Osredkar, Tina Kurent, Teja Fabjan, Kristina Kumer, Elizabeta Božnar Alič & David Drobne. (2021) The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. Biochemia Medica 31:2.
Crossref
Konstantinos Papamichael & Adam S. Cheifetz. (2021) Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 19:4, pages 854-855.
Crossref
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine & Frank M Ruemmele. (2021) The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 15:2, pages 171-194.
Crossref
Amandine Landemaine, Antoine Petitcollin, Charlène Brochard, Céline Miard, Marie Dewitte, Eric Le Balc’h, Thomas Grainville, Eric Bellissant, Laurent Siproudhis & Guillaume Bouguen. (2021) Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection. Clinical Gastroenterology and Hepatology 19:2, pages 288-295.e4.
Crossref
Sebastian Stefanovic, Iris Detrez, Griet Compernolle, Els Brouwers, Nejc Sever, Borut Stabuc, Natasa Smrekar, Tina Kurent, Gregor Novak, Matic Kozelj, Marc Ferrante, Ann Gils & David Drobne. (2020) Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. European Journal of Gastroenterology & Hepatology 33:1, pages 54-61.
Crossref
Walter Reinisch, Krisztina Gecse, Jonas Halfvarson, Peter M Irving, Jørgen Jahnsen, Laurent Peyrin-Biroulet, Gerhard Rogler, Stefan Schreiber & Silvio Danese. (2021) Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflammatory Bowel Diseases 27:1, pages 106-122.
Crossref
Maria M. E. Jongsma, Dwight A. Winter, Hien Q. Huynh, Lorenzo Norsa, Seamus Hussey, Kaija-Leena Kolho, Jiri Bronsky, Amit Assa, Shlomi Cohen, Raffi Lev-Tzion, Stephanie Van Biervliet, Dimitris Rizopoulos, Tim G. J. de Meij, Dror S. Shouval, Eytan Wine, Victorien M. Wolters, Christine Martinez-Vinson & Lissy de Ridder. (2020) Infliximab in young paediatric IBD patients: it is all about the dosing. European Journal of Pediatrics 179:12, pages 1935-1944.
Crossref
Tomohiro Fukuda, Makoto Naganuma, Kaoru Takabayashi, Yuya Hagihara, Shun Tanemoto, Ena Nomura, Yusuke Yoshimatsu, Shinya Sugimoto, Kosaku Nanki, Shinta Mizuno, Yohei Mikami, Kayoko Fukuhara, Tomohisa Sujino, Makoto Mutaguchi, Nagamu Inoue, Haruhiko Ogata, Yasushi Iwao, Takayuki Abe & Takanori Kanai. (2020) Mucosal concentrations of N ‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine . Journal of Gastroenterology and Hepatology 35:11, pages 1878-1885.
Crossref
Amit Assa, Lev Dorfman, Dror S. Shouval, Raanan Shamir & Shlomi Cohen. (2020) Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series. Journal of Pediatric Gastroenterology & Nutrition 71:4, pages 516-520.
Crossref
Xue-Liang Sun, Shi-Yi Chen, Shan-Shan Tao, Li-Chao Qiao, Hong-Jin Chen & Bo-Lin Yang. (2020) Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World Journal of Gastroenterology 26:14, pages 1554-1563.
Crossref
Bram Verstockt, Evelien Mertens, Erwin Dreesen, An Outtier, Maja Noman, Sophie Tops, Ganel Schops, Gert Van Assche, Séverine Vermeire, Ann Gils & Marc Ferrante. (2020) Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Journal of Crohn's and Colitis 14:3, pages 332-341.
Crossref
David J. Gibson, Mark G. Ward, Clarissa Rentsch, Antony B. Friedman, Kirstin M. Taylor, Miles P. Sparrow & Peter R. Gibson. (2020) Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 51:6, pages 612-628.
Crossref
Thomas X. Lu & Russell D. Cohen. (2019) Maneuvering Clinical Pathways for Crohn’s Disease. Current Gastroenterology Reports 21:5.
Crossref
David Drobne, Tina Kurent, Saša Golob, Polona Švegl, Polona Rajar, Jurij Hanžel, Matic Koželj, Gregor Novak, Nataša Smrekar, Ivan Ferkolj & Borut Štabuc. (2019) Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 49:7, pages 880-889.
Crossref
Bram Verstockt, Sare Verstockt, Brecht Creyns, Sophie Tops, Gert Van Assche, Ann Gils, Jan L. Ceuppens, Séverine Vermeire, Marc Ferrante & Christine Breynaert. (2019) Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. Alimentary Pharmacology & Therapeutics 49:5, pages 572-581.
Crossref
Luis Eduardo Miani Gomes, Francesca Aparecida Ramos da Silva, Lívia Bitencourt Pascoal, Renato Lazarin Ricci, Guilherme Nogueira, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, João José Fagundes & Raquel Franco Leal. (2019) Authors' Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?. Clinics 74, pages e1517.
Crossref
Camille Lucidarme, Antoine Petitcollin, Charlène Brochard, Laurent Siproudhis, Marie Dewitte, Amandine Landemaine, Eric Bellissant & Guillaume Bouguen. (2019) Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Alimentary Pharmacology & Therapeutics 49:2, pages 147-154.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.